Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus files NDA for new tablet formulation of heartburn drug
The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor, with a mix of buffers. The new drug application (NDA) was submitted under section
The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor, with a mix of buffers. The new drug application (NDA) was submitted under section
The recommendation specifies the use of Revlimid, in combination with dexamethasone, as an option for the treatment of patients with multiple myeloma who have received two or more
Under the terms of the agreement, the two companies will collaborate on customized marketing promotions to MedAssets’s customers. The LifeSync wireless ECG system offers patient safety and productivity
Certain transitional activities will be continued at the facility for the next few weeks to ensure proper and compliant closure of the facility, however as of January 31,
The collaboration between Novartis and Gen-Probe was established in 1998. It was previously scheduled to expire in 2013. Under the original terms of the agreement, the companies shared
Upon investigational new drug and investigational medicinal product dossier clearance by the regulatory authorities, Pluristem plans to initiate clinical trials in Europe and in the US, administering PLX-PAD
These funds will enable Arcxis to accelerate development, testing, and commercialization of their innovative nucleic acid sample preparation platform and their next generation sample to answer clinical molecular
Mr Conterno will succeed Deirdre Connelly, who has led Lilly’s US operations since 2005. Ms Connelly has resigned from the company to pursue other opportunities. Mr Conterno will
Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. Warner Chilcott has previously announced the filing of
Zoll Medical is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation technologies, ventilation, and fluid resuscitation, Zoll provides a